leisure time -WSS

leisure time

author：knowledge 2025-09-03 22:35:29 - browse：4538

When Prozac first entered the psychiatry scene in in the late ’80s, the profession was still Freud’s territory. Many considered taking medication to treat depression a failure. But that was all about to change, as early stewards like psychiatrist Peter Kramer refused to shy away from the new drug’s potential. These days, he says that people take for granted all of the progress that’s been made with antidepressant treatment in the past three decades.

“If you were going to be depressed any time in history and were interested in having an effective treatment, you would want to be alive now. But we’ve lost our wonderment about that,” said Kramer, the author of the groundbreaking 1993 book “Listening to Prozac.”

This week, Kramer joins me to discuss how the country’s relationship with antidepressants has changed since the publication of his book three decades ago. The conversation is based on his First Opinion, “What antidepressants are saying 30 years after the publication of ‘Listening to Prozac.’”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, Google Play, or wherever you get your podcasts. And don’t forget to sign up for the First Opinion newsletter to read each week’s best First Opinion essays.

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： What will Novo Nordisk's VC do with its influx of cash?

WSS

Congress extends some pandemic preparedness programs

The stability of $0 premiums in Medicare Advantage

Companies helping big Covid

Tommy Tuberville reverses his claim that white nationalists are unfairly labeled racist

The biotech scorecard for Q4: 16 stock

Health insurers' Q3 question: how much care are people getting?

entertainment

leisure time

explore

Trump demands the U.S. pay no more for drugs than other countries … again

WHO recommends second malaria vaccine

How one medical school became remarkably diverse

Kerry to visit Beijing for climate talks amid efforts to revive relations between US and China

ChatGPT in medicine: STAT answers readers' burning questions

Digital health funding stays low as a new reality sets in

Jerome Adams on the need for new antivirals for Covid

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

In Memoriam: Notable people who died in 2023

What will Novo Nordisk's VC do with its influx of cash?

Wikipedia

New oral drug delivery patch is modeled after octopus tentacles

The stability of $0 premiums in Medicare Advantage

With Roe v Wade overturned, abortion providers work to adapt

The stability of $0 premiums in Medicare Advantage

2023 Nobel Prize in Medicine goes to Karikó and Weissman

6 solutions to address cancer drug shortages and others

focus

knowledge

focus

explore